Literature DB >> 18510338

Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution.

Marina A Dobrovolskaia1, Parag Aggarwal, Jennifer B Hall, Scott E McNeil.   

Abstract

Nanoparticles have unique physicochemical properties which make them promising platforms for drug delivery. However, immune cells in the bloodstream (such as monocytes, platelets, leukocytes, and dendritic cells) and in tissues (such as resident phagocytes) have a propensity to engulf and eliminate certain nanoparticles. A nanoparticle's interaction with plasma proteins (opsonins) and blood components (via hemolysis, thrombogenicity and complement activation) may influence uptake and clearance and hence potentially affect distribution and delivery to the intended target sites. Nanoparticle uptake by the immune cells is influenced by many factors. Different nanoparticles have been shown to act on different pathways, while various characteristics/properties also affect which pathway is employed for particle internalization. Nanoparticle protein binding occurs almost instantaneously once the particle enters biological medium, and the physical properties of such a particle-protein complex are often different than those of the formulated particle. These new properties can contribute to different biological responses and change nanoparticle biodistribution. Therefore, in the situation when specific delivery to immune cells is not desired, the ideal nanoparticle platform is the one whose integrity is not disturbed in the complex biological environment, which provides extended circulation in the blood to maximize delivery to the target site, is not toxic to blood cellular components, and is "invisible" to the immune cells which can remove it from circulation. This review discusses the most recent data on nanoparticle interactions with blood components and how particle size and surface charge define their hematocompatibility. This includes properties which determine particle interaction with plasma proteins and uptake by macrophages. We will also provide an overview of in vitro methods useful in identifying interactions with components of the immune system and the potential effects of such interaction on particle distribution to tissues.

Entities:  

Mesh:

Year:  2008        PMID: 18510338      PMCID: PMC2613572          DOI: 10.1021/mp800032f

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  40 in total

1.  Metalloproteinase and cytokine production by THP-1 macrophages following exposure to chitosan-DNA nanoparticles.

Authors:  Fatiha Chellat; Alexia Grandjean-Laquerriere; Richard Le Naour; Julio Fernandes; L'Hocine Yahia; Moncef Guenounou; Dominique Laurent-Maquin
Journal:  Biomaterials       Date:  2005-03       Impact factor: 12.479

2.  In vivo tumor targeting of tumor necrosis factor-alpha-loaded stealth nanoparticles: effect of MePEG molecular weight and particle size.

Authors:  Chao Fang; Bin Shi; Yuan-Ying Pei; Ming-Huang Hong; Jiang Wu; Hong-Zhuan Chen
Journal:  Eur J Pharm Sci       Date:  2005-09-16       Impact factor: 4.384

3.  Nanoparticle-induced platelet aggregation and vascular thrombosis.

Authors:  Anna Radomski; Paul Jurasz; David Alonso-Escolano; Magdalena Drews; Maria Morandi; Tadeusz Malinski; Marek W Radomski
Journal:  Br J Pharmacol       Date:  2005-11       Impact factor: 8.739

4.  Hemolytic effects of water-soluble fullerene derivatives.

Authors:  Susanna Bosi; Luigi Feruglio; Tatiana Da Ros; Giampiero Spalluto; Barbara Gregoretti; Michela Terdoslavich; Giuliana Decorti; Sabina Passamonti; Stefano Moro; Maurizio Prato
Journal:  J Med Chem       Date:  2004-12-30       Impact factor: 7.446

Review 5.  The role of complement in inflammation and phagocytosis.

Authors:  M M Frank; L F Fries
Journal:  Immunol Today       Date:  1991-09

Review 6.  Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles.

Authors:  Donald E Owens; Nicholas A Peppas
Journal:  Int J Pharm       Date:  2005-11-21       Impact factor: 5.875

7.  Protein adsorption patterns on poloxamer- and poloxamine-stabilized solid lipid nanoparticles (SLN).

Authors:  Torsten M Göppert; Rainer H Müller
Journal:  Eur J Pharm Biopharm       Date:  2005-08       Impact factor: 5.571

8.  Blood compatibility of cetyl alcohol/polysorbate-based nanoparticles.

Authors:  J M Koziara; J J Oh; W S Akers; S P Ferraris; R J Mumper
Journal:  Pharm Res       Date:  2005-08-26       Impact factor: 4.200

9.  Phagocytic uptake and cytotoxicity of solid lipid nanoparticles (SLN) sterically stabilized with poloxamine 908 and poloxamer 407.

Authors:  R H Müller; S Maassen; H Weyhers; W Mehnert
Journal:  J Drug Target       Date:  1996       Impact factor: 5.121

10.  Interaction of PLGA nanoparticles with human blood constituents.

Authors:  D Kim; H El-Shall; D Dennis; T Morey
Journal:  Colloids Surf B Biointerfaces       Date:  2005-02-10       Impact factor: 5.268

View more
  218 in total

Review 1.  Best practices in cancer nanotechnology: perspective from NCI nanotechnology alliance.

Authors:  William C Zamboni; Vladimir Torchilin; Anil K Patri; Jeff Hrkach; Stephen Stern; Robert Lee; Andre Nel; Nicholas J Panaro; Piotr Grodzinski
Journal:  Clin Cancer Res       Date:  2012-06-05       Impact factor: 12.531

2.  Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy.

Authors:  Nagesh Kolishetti; Shanta Dhar; Pedro M Valencia; Lucy Q Lin; Rohit Karnik; Stephen J Lippard; Robert Langer; Omid C Farokhzad
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-04       Impact factor: 11.205

3.  Complement Inhibitors Block Complement C3 Opsonization and Improve Targeting Selectivity of Nanoparticles in Blood.

Authors:  Hanmant Gaikwad; Yue Li; Geoffrey Gifford; Ernest Groman; Nirmal K Banda; Laura Saba; Robert Scheinman; Guankui Wang; Dmitri Simberg
Journal:  Bioconjug Chem       Date:  2020-06-29       Impact factor: 4.774

4.  Impact of silica nanoparticle design on cellular toxicity and hemolytic activity.

Authors:  Tian Yu; Alexander Malugin; Hamidreza Ghandehari
Journal:  ACS Nano       Date:  2011-06-08       Impact factor: 15.881

Review 5.  Factors influencing the use and interpretation of animal models in the development of parenteral drug delivery systems.

Authors:  Marilyn N Martinez
Journal:  AAPS J       Date:  2011-10-05       Impact factor: 4.009

6.  Effects of block copolymer properties on nanocarrier protection from in vivo clearance.

Authors:  Suzanne M D'Addio; Walid Saad; Steven M Ansell; John J Squiers; Douglas H Adamson; Margarita Herrera-Alonso; Adam R Wohl; Thomas R Hoye; Christopher W Macosko; Lawrence D Mayer; Christine Vauthier; Robert K Prud'homme
Journal:  J Control Release       Date:  2012-06-23       Impact factor: 9.776

7.  Nanoparticle-induced unfolding of fibrinogen promotes Mac-1 receptor activation and inflammation.

Authors:  Zhou J Deng; Mingtao Liang; Michael Monteiro; Istvan Toth; Rodney F Minchin
Journal:  Nat Nanotechnol       Date:  2010-12-19       Impact factor: 39.213

8.  Biodegradable optode-based nanosensors for in vivo monitoring.

Authors:  Mary K Balaconis; Heather A Clark
Journal:  Anal Chem       Date:  2012-06-22       Impact factor: 6.986

9.  Translational studies of phenotypic probes for the mononuclear phagocyte system and liposomal pharmacology.

Authors:  Whitney P Caron; John C Lay; Alan M Fong; Ninh M La-Beck; Parag Kumar; Suzanne E Newman; Haibo Zhou; Jane H Monaco; Daniel L Clarke-Pearson; Wendy R Brewster; Linda Van Le; Victoria L Bae-Jump; Paola A Gehrig; William C Zamboni
Journal:  J Pharmacol Exp Ther       Date:  2013-09-16       Impact factor: 4.030

10.  Formation of stable nanocarriers by in situ ion pairing during block-copolymer-directed rapid precipitation.

Authors:  Nathalie M Pinkerton; Arnaud Grandeury; Andreas Fisch; Jörg Brozio; Bernd U Riebesehl; Robert K Prud'homme
Journal:  Mol Pharm       Date:  2012-12-24       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.